Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for Amicus Therapeutics (FOLD) over the last 9 years, with Q1 2020 value amounting to $1.2 million.

  • Amicus Therapeutics' Current Deferred Revenue fell 5454.55% to $1.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.2 million, marking a year-over-year decrease of 5454.55%. This contributed to the annual value of $1.2 million for FY2019, which is 7727.27% down from last year.
  • Amicus Therapeutics' Current Deferred Revenue amounted to $1.2 million in Q1 2020, which was down 5454.55% from $1.2 million recorded in Q4 2019.
  • Amicus Therapeutics' 5-year Current Deferred Revenue high stood at $18.8 million for Q2 2017, and its period low was $1.2 million during Q4 2019.
  • For the 5-year period, Amicus Therapeutics' Current Deferred Revenue averaged around $6.6 million, with its median value being $5.4 million (2018).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 8541.11% in 2018, then surged by 9090.91% in 2019.
  • Amicus Therapeutics' Current Deferred Revenue (Quarter) stood at $13.8 million in 2016, then crashed by 44.04% to $7.8 million in 2017, then fell by 29.03% to $5.5 million in 2018, then crashed by 77.27% to $1.2 million in 2019, then changed by 0.0% to $1.2 million in 2020.
  • Its Current Deferred Revenue was $1.2 million in Q1 2020, compared to $1.2 million in Q4 2019 and $5.2 million in Q3 2019.